RxDoctor Payments Data

Jinesh Shah, MD

Radiation Oncology · Bronx, NYNPI 1669687927

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Novartis at 39.8% of the total. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,112in general payments, 2019–2025

Across 20 payments — averaging $555.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Avyxa Pharma, LLC$3K
  • Bayer$3K
  • Siemens Medical Solutions USA, Inc.$391
  • Kls-martin L.p.$183
  • Pfizer$36
  • plus $92 from 3 others

What the payments were for

  • Consulting fees$6,62960%
  • Speaking & faculty fees$2,00018%
  • Travel & lodging$1,72716%
  • Food & beverage$7567%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,112 in reported general payments places this provider in the 90th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York

Medicare billing

Part B allowed, 2024
$549,137
Medicare patients
89
Services billed
2,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl79$563
Oxybutynin Chloride ErOxybutynin Chloride11$89
Diazepam18$3

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →